Login to Your Account



MacroGenics 'Serves' DART Deal Worth Potential $1B

By Peter Winter
BioWorld Insight Editor

Thursday, September 20, 2012
MacroGenics' DART technology for generating bi‐specific antibodies has attracted a great deal of interest from pharmaceutical and biotechnology companies. In the past couple of years the company has forged alliances with Boehringer Ingelheim, Green Cross (Korea), Pfizer Inc. and Servier. The latest deal brings Servier back to the table.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription